Jade Biosciences, Inc.(JBIO)

Biotechnology · Waltham, MA

$13.33-0.74 (-5.26%)

Delayed quote: Oct 6, 2026, 10:14 AM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T14:17:12.500Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:17:12.500Z.

Quote observation: 2026-10-06T14:14:55.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 811,262,089
Total debt · period ending 2026-06-30: 628,000
Cash · period ending 2026-06-30: 107,250,000
TTM free cash flow · period ending 2026-06-30: -123,570,000

FMP input reference: 7de7752a9f7c92cf302168b3adc2b8952dbd3ee015c15fa7e623ade4200d4f53

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

JBIO EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

JBIO Competitors' EV/FCF Ratio

JBIO

Jade Biosciences, Inc.

Current

Market Cap

$811.26M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INMD

InMode Ltd.

vs JBIO

Market Cap

$809.46M

EV/FCF Ratio

4.78x

TTM Avg

6.37x

3Y Avg

8.04x

5Y Avg

13.91x

ARDX

Ardelyx, Inc.

vs JBIO

Market Cap

$807.78M

EV/FCF Ratio

N/A

TTM Avg

4.50x

3Y Avg

4.50x

5Y Avg

4.50x

APMD

Apnimed, Inc.

vs JBIO

Market Cap

$817.17M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GYRE

Gyre Therapeutics, Inc.

vs JBIO

Market Cap

$804.95M

EV/FCF Ratio

N/A

TTM Avg

402.12x

3Y Avg

246.51x

5Y Avg

209.59x

AHCO

AdaptHealth Corp.

vs JBIO

Market Cap

$790.47M

EV/FCF Ratio

28.79x

TTM Avg

18.09x

3Y Avg

34.83x

5Y Avg

61.33x

ALMS

Alumis Inc.

vs JBIO

Market Cap

$823.91M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BBNX

Beta Bionics, Inc.

vs JBIO

Market Cap

$832.08M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GLUE

Monte Rosa Therapeutics, Inc.

vs JBIO

Market Cap

$839.81M

EV/FCF Ratio

N/A

TTM Avg

10.33x

3Y Avg

10.33x

5Y Avg

10.33x

MLAB

Mesa Laboratories, Inc.

vs JBIO

Market Cap

$777.46M

EV/FCF Ratio

16.04x

TTM Avg

16.95x

3Y Avg

18.56x

5Y Avg

27.11x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Jade Biosciences, Inc. (JBIO)	$811.26M	N/A	N/A	N/A	N/A
InMode Ltd. (INMD)vs ›	$809.46M	4.78x	6.37x	8.04x	13.91x
Ardelyx, Inc. (ARDX)vs ›	$807.78M	N/A	4.50x	4.50x	4.50x
Apnimed, Inc. (APMD)vs ›	$817.17M	N/A	N/A	N/A	N/A
Gyre Therapeutics, Inc. (GYRE)vs ›	$804.95M	N/A	402.12x	246.51x	209.59x
AdaptHealth Corp. (AHCO)vs ›	$790.47M	28.79x	18.09x	34.83x	61.33x
Alumis Inc. (ALMS)vs ›	$823.91M	N/A	N/A	N/A	N/A
Beta Bionics, Inc. (BBNX)vs ›	$832.08M	N/A	N/A	N/A	N/A
Monte Rosa Therapeutics, Inc. (GLUE)vs ›	$839.81M	N/A	10.33x	10.33x	10.33x
Mesa Laboratories, Inc. (MLAB)vs ›	$777.46M	16.04x	16.95x	18.56x	27.11x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

JBIO EV/FCF Ratio Metrics

JBIO Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics